Sarepta Therapeutics, Inc.
SRPT
Rank in Stocks
#6250
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company... Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company dedicated to the discovery and advancement of genetic treatment modalities, including RNA-targeted therapeutics and gene therapies, specifically for rare diseases. The company currently offers two approved treatments: EXONDYS 51, prescribed for Duchenne muscular dystrophy (DMD) patients with confirmed dystrophin gene mutations amenable to exon 51 skipping, and VYONDYS 53, for DMD patients with exon 53 skipping mutations. Sarepta's development pipeline includes AMONDYS 45, an exon-skipping product candidate utilizing phosphorodiamidate morpholino oligomer chemistry for exon 45; SRP-5051, a peptide-conjugated PMO designed to target exon 51 of dystrophin pre-mRNA; and gene therapy programs such as SRP-9001 for DMD and SRP-9003 for limb-girdle muscular dystrophies. The company maintains collaborative agreements with organizations like F. Hoffman-La Roche Ltd, Nationwide Children's Hospital, Lysogene, Duke University, Genethon, and StrideBio. Founded in 1980, Sarepta Therapeutics is headquartered in Cambridge, Massachusetts.
Share Price
$17.24
Last synced: 2026-11-09
Market Cap
$1.82B
Change (1 day)
-3.25%
Change (1 year)
-4.12%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Sarepta Therapeutics, Inc. (SRPT)
Category
Healthcare
Operating Margin for Sarepta Therapeutics, Inc. (SRPT)
Operating Margin as of November 2026 TTM: -7.26%
According to Sarepta Therapeutics, Inc.'s latest financial reports, its current operating margin (TTM) is -7.26%. At the end of 2025 the company had an operating margin of -29.92%.
Operating Margin history for Sarepta Therapeutics, Inc. from 2000 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | -7.26% | -75.74% |
| 2025 | -29.92% | -360.85% |
| 2024 | 11.47% | -153.25% |
| 2023 | -21.54% | -62.52% |
| 2022 | -57.47% | -12.26% |
| 2021 | -65.50% | -37.30% |
| 2020 | -104.46% | -43.62% |
| 2019 | -185.27% | 62.30% |
| 2018 | -114.15% | 2.81% |
| 2017 | -111.03% | -97.74% |
| 2016 | -4,920.31% | -72.00% |
| 2015 | -17,572.55% | 1,181.54% |
| 2014 | -1,371.21% | 115.96% |
| 2013 | -634.95% | 697.98% |
| 2012 | -79.57% | 4.07% |
| 2011 | -76.46% | 7.45% |
| 2010 | -71.16% | -19.30% |
| 2009 | -88.18% | -31.73% |
| 2008 | -129.16% | -57.14% |
| 2007 | -301.38% | -98.95% |
| 2006 | -28,608.52% | 7,713.12% |
| 2005 | -366.16% | -93.71% |
| 2004 | -5,817.95% | 198.97% |
| 2003 | -1,945.99% | -35.74% |
| 2002 | -3,028.39% | 38.83% |
| 2001 | -2,181.36% | 176.33% |
| 2000 | -789.41% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 38.59% | -105.32% |
US
|
|
| -149.01% | -79.48% |
US
|
|
| 25.57% | -103.52% |
AU
|
|
| 31.23% | -104.30% |
BE
|
|
| 29.35% | -104.04% |
NL
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about Sarepta Therapeutics, Inc.'s operating margin
What is Sarepta Therapeutics, Inc.'s operating margin?
Sarepta Therapeutics, Inc.'s operating margin is -7.26%, as of Nov 2026.
What was Sarepta Therapeutics, Inc.'s operating margin in 2025?
In 2025, Sarepta Therapeutics, Inc.'s operating margin was -29.92%, compared with 11.47% in 2024.
How has Sarepta Therapeutics, Inc.'s operating margin changed since 2020?
From 2020 to 2025, Sarepta Therapeutics, Inc.'s operating margin was highest in 2024 (11.47%) and lowest in 2020 (-104.46%).
How does Sarepta Therapeutics, Inc.'s operating margin compare with similar companies?
Sarepta Therapeutics, Inc.'s operating margin (-7.26%) is higher than that of 1 of the 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 38.59%.